<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139462">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285453</url>
  </required_header>
  <id_info>
    <org_study_id>CASA404A1102</org_study_id>
    <nct_id>NCT01285453</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors</brief_title>
  <official_title>A Safety, Tolerability Study of Intravenous ASA404 Administered in Combination With Docetaxel in Japanese Patients With Advanced or Recurrent Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the tolerability of combination therapy with ASA404 and docetaxel in
      Japanese patients with advanced or recurrent solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Advanced or Recurrent Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ASA404</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vadimezan</intervention_name>
    <arm_group_label>ASA404</arm_group_label>
    <other_name>ASA404</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with confirmed solid tumors whose disease has progressed or recurred after
             treatment at lease one therapy, except docetaxel

          2. WHO Performance Status of 0-1

        Exclusion Criteria:

          1. Patients having symptomatic CNS tumor/metastasis and requiring treatment

          2. Patients who have received prior therapy with ASA404 or other vascular disrupting
             agents

          3. Patients with systolic BP &gt; 160mmHg and/or diastolic BP &gt; 90mmHg

          4. Patients with fluid retention

          5. Patients with any one of cardiotoxicities

          6. Concomitant use of drugs with a risk of prolonging the QT interval

          7. Known allergy or hypersensitivity to taxane or polysorbate 80

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 26, 2012</lastchanged_date>
  <firstreceived_date>January 26, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASA404,</keyword>
  <keyword>vadimezan,</keyword>
  <keyword>docetaxel</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vadimezan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
